Drug company Knopp Biosciences has announced the addition of C. David Adair to its Board of Managers. Dr. Adair is the managing director at Solas BioVentures, the company that has agreed an equity financing arrangement with Knopp Biosciences for approximately $14 million.
“Knopp is excited to enter 2021 well-positioned to complete our Phase 2 dexpramipexole asthma trial and to initiate IND-enabling studies and Phase 1 trials of KB-3061,” said Knopp president and CEO Michael Bozik. “We’re grateful for the capital and commitment Solas BioVentures brings to our team and the expertise and experience that Dave Adair brings to our Board of Managers.”
Dr. Adair was a founding member of Solas BioVentures in 2014, and has more than 20 years of experience as a venture investor. He is a former Professor and Vice Chair of Obstetrics and Gynecology at the University of Tennessee College of Medicine, and is Board certified in maternal-fetal medicine, obstetrics and gynecology, and hypertension.
“I’m pleased to join the Knopp team as it enters a pivotal year of milestone attainment,” said Dr. Adair. “Our investing philosophy at Solas BioVentures fits squarely within Knopp’s emphasis on unmet medical need, breakthrough technology, and leadership tenacity."